Gastroprotective, promotility agents fail to prevent systemic sclerosis-associated ILD

Gastroprotective, promotility agents fail to prevent systemic sclerosis-associated ILD

Gastroprotective and promotility agents do not appear to prevent clinically apparent systemic sclerosis-associated interstitial lung disease, according to results of a large retrospective cohort study.“Given the potential association between GERD and progressive systemic sclerosis-associated ILD, treatment of GERD with gastroprotective agents is recommended in the setting of systemic sclerosis-associated ILD when concomitant GERD is present,” Raphaël Hurtubise, MD, internal medicine resident at Montreal University, and colleagues wrote in Respiratory Medicine. “However, itRead More

Share on facebook
Share on twitter
Share on linkedin